Literature DB >> 15111929

CD25 expression distinguishes functionally distinct alloreactive CD4 CD134 (OX40) T-cell subsets in acute graft-versus-host disease.

Philip R Streeter1, Xingqi Zhang, Thomas V Tittle, Catherine N Schön, Andrew D Weinberg, Richard T Maziarz.   

Abstract

CD134 (OX40) is expressed on activated CD4(+) donor T cells in allogeneic stem cell transplant recipients with acute graft-versus-host disease. The data presented here reveal that differential expression of CD25 by CD4(+) CD134(+) T cells allows separation of these activated cells into 2 phenotypically and functionally distinct alloreactive T-cell subsets. These subsets exhibit distinct tissue associations, with CD4(+) CD134(+) CD25(-) T cells preferentially found in lymphoid tissues and CD4(+) CD134(+) CD25(+) T cells located in lymphoid tissues and inflamed extralymphoid tissues. The CD25(-) T-cell subset exhibited potent proliferative responses to both concanavalin A and allogeneic host leukocytes. By contrast, the CD25(+) T-cell subset proliferated minimally in response to either treatment and inhibited alloantigen-induced proliferation of the CD25(-) subset. Proliferative unresponsiveness associated with the CD25(+) T-cell subset did not extend to cytokine secretion. When stimulated with alloantigen, both CD4(+) CD134(+) T-cell subsets responded by secreting interferon-gamma and interleukin (IL)-10, and neither T-cell subset produced detectable levels of IL-2 or IL-4. Three-day treatment of the CD25(+) T-cell subset with IL-2 restored the proliferative responsiveness of these cells to host alloantigens, suggesting that the proliferative unresponsiveness associated with this T-cell subset reflected a requirement for IL-2. The preferential tissue associations and distinct functional properties associated with these separable alloreactive CD4(+) CD134(+) T-cell subsets suggest that they participate differentially in clinical graft-versus-host disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15111929     DOI: 10.1016/j.bbmt.2003.12.302

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  4 in total

1.  Expression of OX40 (CD134) on CD4+ T-cells from patients with myasthenia gravis.

Authors:  Zhao Xiaoyan; R Pirskanen; V Malmstrom; A K Lefvert
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

2.  An Animal Model That Mimics Human Herpesvirus 6B Pathogenesis.

Authors:  Bochao Wang; Yasuyuki Saito; Mitsuhiro Nishimura; Zhenxiao Ren; Lidya Handayani Tjan; Alaa Refaat; Rie Iida-Norita; Ryuko Tsukamoto; Masato Komatsu; Tomoo Itoh; Takashi Matozaki; Yasuko Mori
Journal:  J Virol       Date:  2020-02-28       Impact factor: 5.103

3.  SHIP limits immunoregulatory capacity in the T-cell compartment.

Authors:  Michelle M Collazo; Daniela Wood; Kim H T Paraiso; Erin Lund; Robert W Engelman; Cam-Tien Le; Diana Stauch; Katja Kotsch; William G Kerr
Journal:  Blood       Date:  2009-01-09       Impact factor: 22.113

4.  Aberrant Expression of Novel Cytokine IL-38 and Regulatory T Lymphocytes in Childhood Asthma.

Authors:  Man Chu; Ida M T Chu; Edmund C M Yung; Christopher W K Lam; Ting F Leung; Gary W K Wong; Chun K Wong
Journal:  Molecules       Date:  2016-07-18       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.